|
"Let us struggle together against AIDS"
August 13, 2008
RFS Pharma and WACKER Announce Assignment Agreement for an Improved Synthetic Process to Manufacture Amdoxovir®
Full Text
SOURCE: RFS Pharma, LLC
February 6, 2008
RFS Pharma Announces a 2 log Plasma Viral Load Decline Following 10 Day Treatment with a Dual Combination of Amdoxovir® (DAPD) and Retrovir® (AZT) in HIV-1 Infected Individuals.
Full Text
SOURCE: RFS Pharma, LLC
June 19, 2007
RFS Pharma, LLC and Genoscience Pharma Sign Joint Venture Agreement to Discover and Develop Protease Inhibitors
Full Text
SOURCE: RFS Pharma, LLC
May 29, 2007
RFS Pharma, LLC Awarded NIH Grant to Develop Resistance Repellent Anti-HIV Drugs
Full Text
SOURCE: RFS Pharma, LLC
October 4, 2006
RFS Pharma, LLC Announces ACLIRES International Ltd. to Conduct Phase 2 HIV Study
Full Text
SOURCE: RFS Pharma, LLC
May 7, 2006
RFS Pharma Announces Appointment of Dr. Steven J. Coats as Senior Director of Chemistry
Full Text
SOURCE: RFS Pharma, LLC
February 13, 2006
RFS Pharma Announces 2-Week Data from an NIH-Sponsored Phase 2 Clinical Trial Evaluating Amdoxovir® (AMDX) in Highly Treatment-Experienced HIV-1 Infected Individuals
Full Text
SOURCE: RFS Pharma, LLC
For more information about these press releases, or about RFS Pharma in general, please contact us.
|
